At a glance
ClinicalIndex Comparison RecordPhase 2Active· 60 enrolled
Drug / intervention
ACP-196 (acalabrutinib)drug
Likely dose
ACP-196 (acalabrutinib) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
In Brief
A Phase 2 clinical trial evaluating ACP-196 (acalabrutinib) for Chronic Lymphocytic Leukemia. Active but no longer recruiting, targeting 60 participants across 23 sites in 6 countries.
Detailed Summary
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesBelgium, France, Israel, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2ActiveOverdue
20162017201820192020202120222023202420252026
Enrollment StartMar 2016
First PostedMar 2016
Primary CompletionOct 2020
Study CompletionJun 2026
TodayJul 2026
First PostedMar 24, 2016
Enrollment StartMar 8, 2016
Primary CompletionOct 16, 2020
Study CompletionJun 6, 2026
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 10.3 years ago
Interventions
ACP-196 (acalabrutinib)drug
ACP-196 100 mg to be administered orally (PO) twice a day BID.